Journal article
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin
Abstract
The eukaryotic translation initiation factor eIF4E is elevated in 30% of malignancies including M4/M5 subtypes of acute myeloid leukemia (AML). The oncogenic potential of eIF4E arises from its ability to bind the 7-methyl guanosine (m(7)G) cap on mRNAs, thereby selectively enhancing eIF4E-dependent nuclear mRNA export and translation. We tested the clinical efficacy of targeting eIF4E in M4/M5 AML patients with a physical mimic of the m(7)G …
Authors
Assouline S; Culjkovic B; Cocolakis E; Rousseau C; Beslu N; Amri A; Caplan S; Leber B; Roy D-C; Miller WH
Journal
Blood, Vol. 114, No. 2, pp. 257–260
Publisher
American Society of Hematology
Publication Date
July 9, 2009
DOI
10.1182/blood-2009-02-205153
ISSN
0006-4971